Feature | August 23, 2012

Generic Clopidogrel Will Contract U.S. Market, Before the Uptake of Novel Agents Increases

In PCI-treated patients in the acute setting, increasing use Angiomax and otamixaban will expand the market over the next decade

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially contract from just under $2 billion in 2011 to about $1.6 billion in 2013, mainly as a result of the U.S. genericization of clopidogrel (Bristol-Myers Squibb/Sanofi’s Plavix) in 2012. Decision Resources forecasts that the post-hospital acute coronary syndrome antiplatelet/anticoagulant market will then expand to almost $2.7 billion in 2021, owing largely to uptake of oral agents with novel modes of action, such as AstraZeneca’s ticagrelor (Brilinta) and the CETP inhibitors, Merck’s anacetrapib and Eli Lilly’s evacetrapib.

“We expect anacetrapib to be the first CETP inhibitor to launch for acute coronary syndrome in 2018, followed by evacetrapib in 2019,” said Decision Resources Analyst Conor Walsh, Ph.D. “We anticipate that these agents will demonstrate significant reductions in cardiovascular events in their Phase III trials, mainly driven by their highly effective LDL-C-lowering abilities. As a result, sales of this drug class are forecast to be $578 million in 2021 in the 12-month post-hospital setting, equivalent to about one-fifth of total sales in this market.”

The Pharmacor advisory service entitled Acute Coronary Syndrome also finds that ticagrelor — approved in Europe in 2010 and in the United States in 2011 — is the drug most likely to change medical practice in acute coronary syndrome. In a Phase III clinical trial, this ADP receptor antagonist significantly reduced the risk of mortality compared with clopidogrel, which has been a mainstay of therapy for the indication.

“In 2021, despite a slow start, we forecast that ticagrelor will earn major-market sales in excess of $650 million for acute coronary syndrome treatment up to 12 months,” Walsh said.

The findings also reveal that, in patients being treated for percutaneous coronary intervention, higher-priced anticoagulants such as The Medicines Company’s bivalirudin (Angiomax)  and Sanofi’s emerging factor Xa antagonist otamixaban will gradually capture share, at the expense of unfractionated heparin. This trend will partly offset the sales decline in this class due to the genericization of Sanofi’s Lovenox/Clexane.

Also, in the acute setting, generic erosion of the glycoprotein (gp) IIb/IIIa inhibitor eptifibatide (Merck/GlaxoSmithKline’s Integrilin) and a general reduction in the use of drugs from this class will be responsible for a drop in market value in excess of $150 million through 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

For more information: www.decisionresources.com

 

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init